Long-term efficacy of antidepressants: Analyzing brain adaptive modifications by Vidal, Rebeca et al.
 1 
Long-term efficacy of antidepressants: analyzing brain 
adaptive modifications. 
 
Rebeca Vidal, Fuencisla Pilar-Cuellar, Antonio Rodriguez-Gaztelumendi, Jesús 
Pascual, Mª Luisa Rojo, Elena Castro, Alvaro Díaz, Elsa M. Valdizán and Angel 
Pazos* 
 
Department of Physiology and Pharmacology, Faculty of Medicine, University of 
Cantabria, 39011, Santander, Cantabria, Spain.  CIBER de Salud Mental (CIBERSAM), 
Instituto de Salud Carlos III, Spain 
 
 
 
*Corresponding author: Dr Angel Pazos, Department of Physiology and Pharmacology. 
University of Cantabria, Avda. Cardenal Herrera Oria s/n, 39011 Santander, Cantabria, 
Spain. Telephone: (34) 942201985. Fax number: (34)942201903. Email: 
pazosa@unican.es 
 
 
Running title: Antidepressants-induced neural changes 
 2 
Summary 
 
The regulatory changes induced by chronic antidepressants on the different brain 
signalling process has been the subject of study in our group. We here review some of 
the results on this topic. On one side, our efforts have been addressed to the study of the 
coupling of 5-HT1 receptors to G proteins: we have demonstrated that 5-HT1A 
autoreceptors are selectively desensitized by chronic fluoxetine, suggesting that this 
could be one of the reasons of the delayed response of antidepressants. A functional 
desensitization of 5-HT1B receptors has been also found. On the other hand, we have 
focused on the mechanisms involved in neural proliferation, studying 2 possible new 
targets: a) the endocannabinoid system, as we have observed a functional up-regulation 
of CB1 receptor functionality in an animal model of depression (olfactory bulbectomy), 
reversed by fluoxetine; and b) the Wnt- -catenin pathway: an up-regulation of the 
expression of -catenin in hippocampus, in parallel with an increase of cell 
proliferation, has been observed in the hippocampus of rats treated with venlafaxine. 
Taken together, these results provide valuable information about the involvement of 
transductional pathways in the mediation of the effects of antidepressant drugs. 
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 Depressive disorders are debilitating diseases with a high life prevalence
1. 
The 
molecular mechanisms underlying the therapeutic action of antidepressant drugs (ADs) 
are not fully clarified: those most commonly used present as an immediate mechanism 
of action their ability to increase serotonin (5-HT) and/or norepinephrine (NE) brain 
levels. Since the initial introduction of tricyclic compounds, several pharmacological 
groups have been progressively incorporated to the therapy of depressive disorders: in 
this regard, selective inhibitors of 5-HT reuptake (SSRI) have represented a relevant 
landmark in the field. Dual NE and 5-HT reuptake inhibitors (SNRI) are a new 
alternative, still in the frame of monoaminergic acting drugs
2
. A huge number of 
compounds, exploring other non-monoaminergic mechanisms
3
, are currently in 
development, although still without a clinical demonstration of efficacy. 
 Although the increase in monoamine levels is a short-term response of ADs, all these 
drugs need to be administered for at least 2-4 weeks to produce a significant clinical 
improvement. This lag is considered to be necessary for brain adaptive processes to 
occur
4-6
. It has been classically suggested that these long-term processes could be 
related to progressive changes in aminergic neurotransmission. In the recent years, other 
non-exclusive neurobiological theories propose that the functional efficacy of ADs 
could involve modifications in various signaling pathways regulating cellular plasticity 
and survival, leading to trophic responses
7
. 
 The evidence that existing ADs treatments exhibit a limited efficacy and a slow onset 
of action suggests that this therapy has not yet reached their upper limit. Therefore, 
further research on new targets, in addition to increase our knowledge about the 
mechanisms underlying the antidepressant effect, will likely result in the discovery of 
drugs with higher profile of response and faster onset of action. In the last decade, our 
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group has been interested in the analysis of the intracellular mechanisms that are 
modified by chronic antidepressant treatments. This research has been mainly carried 
out in normal animals, but some studies in animal models of depression as well as in 
postmortem brain samples of depressed patients have also been carried out. In the 
following we will review some of this work. 
 
Methods 
  In the studies reviewed below, we have used a number of experimental 
procedures (radiometric labeling, western blot, immunohistochemistry, enzyme 
quantiation, electrophysiology, behavioural approaches) in order to analyze in deep the 
involvement of intracellular mechanisms in the long-term response to antidepressants. 
We will not describe here in detail the different methodological approaches, that are 
fully reported in the original articles presenting these results 
8-11
. 
 
Adaptive changes of monoaminergic systems: the case of 5-HT1 receptors 
 5-HT-mediated neurotransmission is still one of the main identified targets for 
antidepressant action. Chronic administration of ADs results in regulatory changes of 
the different 5-HT receptor subtypes, which could be of relevance for the clinical 
response.  5-HT exerts its actions through at least 14 different receptor subtypes, the 5-
HT1 family, associated to G proteins, is present in high densities through the central 
nervous system. In this regard, our group has devoted considerable effort to analyze the 
modifications induced by ADs on the transductional mechanisms associated to the two 
main 5-HT1 receptor subtypes: 5-HT1A and 5-HT1B.  Indeed, the efficacy in coupling to 
G proteins has been one of the subjects of our study
8
. As it is illustrated in Figure 1A, 
chronic treatment with the SSRI fluoxetine (10 mg/kg, 21 days) induces a differential 
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response in the level of stimulation of [
35
S]GTP S binding, depending on the rat brain 
area analyzed: a significant desensitization is observed in the dorsal raphe, while non-
significant changes occur in the remaining areas examined (i.e. hippocampus). 5-HT1A 
receptors over the dorsal raphe are presynaptic and act as autoreceptors controlling the 
neuronal discharge. A desensitization of 5-HT1A autoreceptors following AD treatment 
has been also found in vivo studies, including electrophysiological recordings
8,12-13
.Our 
results demonstrate that this fluoxetine-induced desensitization of 5-HT1A autoreceptors 
occurs at the G protein level. This finding is of special interest taking into account that it 
has been repeatedly suggested that this desensitization may be critical for the delayed 
onset of the antidepressant effect of SSRI
5
. With respect to 5-HT1B receptors (Figure 
1B), our studies reveal a general response of decrease in their G protein coupling ability 
throughout the rat brain (caudate-putamen, substantia nigra). Recent studies of our 
group show that this tendency to the decrease in 5-HT1B-dependent functionality is also 
present in an animal model of depression (olfactory bulbectomy) in some (substantia 
nigra, -22.7%; dorsal raphe, -31.0%, p<0.05) but not all (caudate-putamen) areas 
(unpublished). The tendency to the functional desensitization of 5-HT1 receptors can be 
explained in terms of regulatory response to the increase in the levels of synaptic 5-
HT
14
, due to the acute inhibition of the reuptake process. Although an exact correlation 
between these changes and the degree of efficacy of ADs is difficult to establish, it is 
tempting to speculate that these adaptive modifications in 5-HT-mediated signal 
transduction are required for the clinical response of these drugs. 
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Is there a role for the endocannabinoid system in the treatment of depression ? : 
the olfactory bulbectomy as a model. 
 Bilateral olfactory bulbectomy (OBX) in the rat is widely used as an animal model of 
depression, as these animals exhibit a number of behavioral, neurochemical and 
structural changes that are reversed by chronic ADs administration
15
. As current data 
suggest that brain endocannabinoid (EC) signalling, mainly through CB1  receptors, 
might be involved in the long-term adaptations induced by ADs, we have used this 
model to clarify this issue
11
. As shown in fig. 2A, an increased CB1 receptor –mediated 
[
35
frontal cortex of OBX animals was found: chronic 
fluoxetine fully reversed this increase.  Interestingly, previous studies have 
demonstrated an elevated CB1 receptor –mediated [
35
S]GTP S binding in cortical samples 
from depressed patients
16
. Our results, in addition to validate the OBX as a model of 
depression, strongly support the involvement of EC signaling in both depression and 
antidepressant mechanisms, as it is illustrated by the absence of modifications in the 
animals receiving chronic fluoxetine. In this regard, it has been shown that CB1 receptor 
knock-out mice exhibit enhanced depressive-like behaviours
17
 and, consistently, acute 
low doses of cannabinoids produce antidepressant-like effects in rodents
18-19
 likely via 
promoting hippocampal neurogenesis
20
. Nevertheless, further studies are required in 
order to fully clarify the role of EC system in depression. 
 
Modulation of neural plasticity circuitry: supporting a trophic response for 
antidepressants 
In the last few years, the interest about the mechanisms of action of 
antidepressants has moved from the receptor level to the intracellular signaling 
cascades
21
. In this regard, the cAMP-CREB transduction pathway has been consistently 
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implicated in the long-term effects of antidepressants. Studies carried out in postmortem 
samples from depressed patients have resulted in contradictory results
22
: we have also 
addressed this issue, finding no significant change in the basal activity of the enzyme 
(adenylate cyclase) in brain samples from a well characterized group of depressed 
patients, with respect to matched controls
9
. However, we found a significant lower 
response to 1-adrenoceptors agonist-stimulated AC activity in the major depression 
group (p <.01) (see Figure 2B). 
It is now well documented that chronic AD treatment enhances cell proliferation 
in adult rodent subgranular zone (SGZ) of hippocampus and that the time required for 
the differentiation and maturation of newborn neurons correlates well with the 
appearance of clinical response to the AD treatment
23
. In line with the new trophic 
hypothesis, we have addressed in detail the modifications induced by the chronic 
administration of the SNRI venlafaxine (40 mg/kg, 14 days) on two intracellular 
proteins involved in neural plasticity: in addition to the expression of CREB and 
pCREB, widely suggested to be involved in AD-induced cellular changes, we have also 
analyzed the expression of -catenin, an emerging candidate to play a key role in 
neuroproliferative processes.  Although the involvement of CREB and pCREB 
expression in the cellular responses induced by antidepressants is widely accepted, the 
nature of this modulation appears to depend on several factors (type of antidepressant, 
doses, route of administration) and contradictory data have been published
24-25
. We have 
found no modification in CREBN and pCREB expression in the hippocampus of rats 
treated with venlafaxine (figure 2D). In contrast, preliminary data from our lab appear 
to indicate that chronic fluoxetine does up-regulate pCREB in the rat brain.  
Wnt-β-catenin cascade regulates the hippocampal neurogenesis in the adult 
brain. Activation of the canonical Wnt pathway leads to the inhibition of GSK-3, 
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allowing β-catenin to be translocated to the nucleus, where activates transcription of 
target genes. We have demonstrated that chronic venlafaxine induces a significant 
increase in the expression of β-catenin in the SZH (figure 2E): an increase in cell 
proliferation, quantified by BrdU immucytochemistry, is observed in the same 
animals
10
. Western blot (figure 2C) and immunoelectron microscopy studies have 
demonstrated an increased presence of β-catenin (+88.0±9 %, western data) at the 
nuclear level
10
. These results suggest that the hippocampal proliferative effect of 
chronic venlafaxine, only evident at a dose that inhibits both 5-HT and NE reuptake 
systems, requires a strong activation of intracellular signaling through Wnt
26
, probably 
resulting in an increase of the expression of cell cycle regulator genes. 
 
Conclusion 
In conclusion, our group is focusing its efforts in the analysis of the modulatory 
changes occurring on the monoaminergic neurotransmission following antidepressant 
treatments, and on the modification of those involving neuroplastic and proliferative 
pathways. We are also interested in the possible interactions between these two types of 
responses. These studies may contribute to the development of new therapeutic targets 
for the depressive disorders, which is the ultimate goal of all our work. 
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Figure 1. 
Effect of chronic fluoxetine treatment (10mg/kg/day, 21 days, p.o) on (A) 5-HT1A  
receptor-mediated stimulation of [
35
S]GTP S binding induced by 8-OH-DPAT (10 M). 
A significant desensitization is observed at dorsal raphe (DRN) autoreceptors, but not at 
postsynaptic receptors (CA1) (B) the 5-HT1B receptor-mediated stimulation of 
[
35
S]GTP S binding induced by 5-HT (10 M) in coronal sections of the rat brain. A 
pattern of decrease is observed following fluoxetine. CA1: CA1 field of hippocampus; 
DG: dentate gyrus; Ent: entorhinal cortex; DRN: dorsal raphe nucleus; CP: caudate 
putamen VP: ventral pallidum; LGP: lateral globus pallidus; SN: substantia nigra. (*p< 
0.05, Student t-test unpaired data).  
 
Figure 2. 
A. Effect of OBX (olfactory bulbectomiced rat) and chronic treatment with fluoxetine 
(10 mg/kg/day, 14 days, minipumps) or vehicle on CB1 receptor-mediated stimulation 
of [
35
S]GTP S binding induced by WIN 55,212-2 (10 M) in rat prefrontal cortical 
membranes. Note that chronic fluoxetine reversed the increased functionality of CB1 
receptors induced by OBX (inserted graph). Data represent the mean ± SEM. Modified 
from Rodriguez-Gaztelumendi et al., 2009. 
B. Effect of increasing concentrations of the specific -adrenoceptor agonist xamoterol 
(1, 10, and 100 M) on cAMP (cyclic adenosine monophosphate) levels (expressed as 
mean ± SEM of the percentage of increase over the basal) in crude membranes from 
postmortem human frontal cortex of control (open bars) and major depression disorder 
(closed bars). **p<0.01 post hoc paired t test after repeated-measures analysis of 
variance. Taken from Valdizán et al., 2003. 
C. Effect of chronic venlafaxine (40 mg/kg/day, 14 days, minipumps) treatment on the 
expression of main effector proteins of Wnt and AKT/PKB signaling pathways. Graphs 
represent relative densitometry levels of -catenin in treated animals as a percentage of 
these proteins in saline group animals (mean ± SEM). Venlafaxine treatment increases 
-catenin immunoreactivity in TCL (total cell lysate), and NF (nuclear fraction) of rat 
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hippocampus in Western blot studies. Densitometric measurement levels were 
normalized to actin protein amounts. 
D. Effect of chronic venlafaxine (40 mg/kg/day, 14 days, minipumps) treatment on the 
expression of CREB and pCREB. Graphs represent relative densitometry levels of 
CREB and pCREB, and pCREB/CREB ratio related to the vehicle group (mean ± SEM) 
of nuclear fractions from rat hippocampus from saline and venlafaxine treated animals 
in Western blot studies. Densitometric measurement levels were normalized to actin 
protein amounts.  
E. β-catenin immunohistochemistry in the subgranular zone (SGZ) of the hippocampus 
of adult rat from vehicle and venlafaxine (40 mg/kg/day, 14 days, minipumps) treated 
animals. β-catenin positive cells were labelled using DAB as a chromogen. Cresyl violet 
was used as counter-staining. The number of β-catenin positive cells in the SGZ is 
significantly increased after chronic treatment with venlafaxine. 
 
 
